Pharma BD Deal Intelligence
TPG Capital exit at $2.9B, characterized by Bloomberg as a clean PE-to-strategic handoff with Forest CEO Brent Saunders citing immediate accretion.
Deal closed Feb 3, 2014 strengthening Forest's US/Canada GI franchise and adding US/EU CF business — financed via cash + $1.8B bond offering.
Six weeks after closing Aptalis, Forest itself was acquired by Actavis for ~$25B — Aptalis assets moved up the chain to Actavis/Allergan within months.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Forest Laboratories agreed to acquire privately held Aptalis for $2.9B in cash from TPG Capital, strengthening Forest's U.S. and Canadian gastrointestinal franchise and adding a U.S./European cystic fibrosis business. Deal closed February 3, 2014; Forest itself was acquired by Actavis four months later.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Forest Laboratories, Inc. / Aptalis Pharma Inc. (this deal) | 2014 | $2.9B | 25 |
| Forest Laboratories, Inc. / Cerexa Inc. | 2006 | $580M | 47 |
| Forest Laboratories, Inc. / Clinical Data, Inc. | 2011 | $1.2B | 37 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
← Browse all deals · How we score deals
More: 2014 deals · Forest Laboratories, Inc. deals · Gastroenterology deals